Question · asked by 1 review
Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron: aprepitant + ramosetron
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic… (2021) · Cochrane Headline outcomes only | no estimate extracted | 23 studies · 16065 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis 2021 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.